Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $243.00

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target raised by stock analysts at Citigroup from $213.00 to $243.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. Citigroup's price objective would suggest a potential upside of 38.37% from the stock's previous close.

ASND has been the subject of a number of other research reports. Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price target for the company. Bank of America raised their target price on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, Royal Bank Of Canada lifted their price objective on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $223.07.

Ascendis Pharma A/S Trading Down 0.5%

Shares of ASND stock traded down $0.87 during trading hours on Friday, hitting $175.62. 282,954 shares of the company were exchanged, compared to its average volume of 505,073. The company has a market capitalization of $10.74 billion, a PE ratio of -27.97 and a beta of 0.38. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The business has a 50 day moving average of $168.22 and a two-hundred day moving average of $153.16.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares during the period. Atria Investments Inc raised its stake in Ascendis Pharma A/S by 19.2% in the fourth quarter. Atria Investments Inc now owns 2,436 shares of the biotechnology company's stock valued at $335,000 after purchasing an additional 393 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $1,725,000. HighTower Advisors LLC purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $484,000. Finally, Corient Private Wealth LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $450,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.